Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ironwood Pharmaceuti (NQ: IRWD )

5.885 +0.305 (+5.47%)
Streaming Delayed Price Updated: 10:11 AM EDT, Jun 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 415,698
Open 5.610
Bid (Size) 5.880 (3)
Ask (Size) 5.890 (11)
Prev. Close 5.580
Today's Range 5.550 - 5.910
52wk Range 5.470 - 15.70
Shares Outstanding 158,957,123
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-52.58%
-52.58%
1 Month
-13.20%
-13.20%
3 Month
-34.83%
-34.83%
6 Month
-46.98%
-46.98%
1 Year
-45.66%
-45.66%

More News

Read More
IRWD Stock Earnings: Ironwood Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech Stocks
Via InvestorPlace
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March
Via Benzinga
It’s Time! 3 Failing Biotech Stocks to Sell Right Now
Via InvestorPlace
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Stocks Mixed, Headed For Monthly Wins
Via Talk Markets
Topics Economy
Exposures Interest Rates
Why Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?
Via Benzinga
Nasdaq Gains 100 Points Following PCE Data
Via Benzinga
Topics Stocks
Exposures US Equities
PSNY Stock Alert: Polestar Makes Moves With Its Joint Venture
Via InvestorPlace
Ironwood Pharmaceuticals Ran Up 32% Over Two Months — And Just Lost It All
Via Investor's Business Daily
Tech Stocks Set To Rise Thursday As January Inflation Data Fails To Scare Markets, Small Caps Surge
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Is Ironwood Pharmaceuticals (IRWD) Stock Down 27% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.